US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SNDK $1,704.16 ▲+0.00% AMD $631.75 ▲+0.00% SDEV $3.94 ▲+0.00% SKHY $195.02 ▲+0.00% TSLA $378.73 ▲+0.00%
FinancialContent

Articles published by Evotec AG

News headline image
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
From Evotec AG
Via AccessWire
Tickers EVO EVOTF
News headline image
Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes
From Evotec AG
Via AccessWire
News headline image
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
From Evotec AG
Via AccessWire
Tickers EVO EVOTF
News headline image
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
From Evotec AG
Via AccessWire
Tickers EVO EVOTF
News headline image
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
From Evotec AG
Via AccessWire
Topics Artificial Intelligence
Tickers EVO
News headline image
Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
From Evotec AG
Via AccessWire
News headline image
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic
From Evotec AG
Via AccessWire
Tickers EVO EVOTF
News headline image
Evotec Receives US$ 18 M Grant for Women's Health
From Evotec AG
Via AccessWire
News headline image
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update
From Evotec AG
Via AccessWire
Topics Initial Public Offering
News headline image
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec SE Announces Closing of Public Offering
From Evotec AG
Via AccessWire
Tickers EVO
News headline image
Evotec SE Announces Placement of Its Public Offering of American Depositary Shares
From Evotec AG
Via AccessWire
Topics Regulatory Compliance
News headline image
Evotec SE To Announce Results for the First Nine Months 2021 On 11 November 2021
From Evotec AG
Via AccessWire
Topics Regulatory Compliance
News headline image
Evotec SE: Announces Launch of Public Offering of American Depositary Shares
From Evotec AG
Via AccessWire
Topics Regulatory Compliance
News headline image
Evotec Provides Preliminary Nine Month Financial Results
From Evotec AG
Via AccessWire
News headline image
Evotec SE files Registration Statement for Proposed Offering of American Depositary Shares
From Evotec AG
Via AccessWire
Topics Regulatory Compliance
News headline image
Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type
From Evotec AG
Via AccessWire
News headline image
Evotec Announces Bristol Myers Squibb Opt-in of EVT8683 as the First Programme from iPSC-based Neurodegeneration Collaboration
From Evotec AG
Via AccessWire
News headline image
Just - Evotec Biologics Opens J.POD 1 US in Redmond, Washington
From Evotec AG
Via AccessWire
News headline image
Evotec SE Reports First Half-Year 2021 Results and Corporate Updates
From Evotec AG
Via AccessWire